Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

Completed

Conditions studied: Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin, Clopidogrel

In brief

The purpose of this study is to assess the the 1-year rates of ischemic and bleeding complications in patients whose dual antiplatelet therapy regimen post-PCI has been determined with the use of a clinical algorithm that includes both clinical risks and platelet reactivity while on chronic clopidogrel therapy.

Key facts

Study ID

NCT01582217

Run by

Icahn School of Medicine at Mount Sinai

People needed

318

Starts

2012-03-01

Expected to finish

2014-12-01

Last updated by the study team

2015-12-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject has provided informed written.
• The subject must be ≥ 18 years of age (or minimum age as required by local regulations) at the time of enrollment.
• Patient is established on chronic clopidogrel therapy when he/she returns for PCI, and the components of DAPT are determined by the clinical decision algorithm as local standard of care.
• The subject is willing and able to cooperate with the study procedures and required follow-ups.

You may not qualify if…

• Patients with cardiogenic shock will be excluded.
• The subject is participating in an investigational device or drug study. Subject must have completed the follow up phase of any previous study at least 30 days prior to enrolment in this study.
• Pregnant women.

Where it is running

• Mount Sinai Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.